Professor Craig Anderson

  • Professor of Stroke Medicine and Clinical Neuroscience, University of Sydney
  • Director, Neurological and Mental Health Division, The George Institute for Global Health
  • Neurologist and Director of Acute Stroke Unit, Royal Prince Alfred Hospital, Sydney South West Area Health Service

Current research interests

  • Accredited medical specialties: Neurology, geriatrics, internal medicine and public health
  • Areas of expertise: Neurology, stroke medicine, gerontology and clinical epidemiology

Major research achivements

Professor Anderson has undertaken several major epidemiological projects in stroke in Australia, New Zealand and China, which have provided new or confirmatory information about the strength and importance of risk factors, and the broad consequences of stroke. The information has been used in policy documents and health service planning, both within Australasia and globally (eg data on stroke was used in the WHO Global Burden of Disease Reports). He has held leadership positions on several major secondary cardiovascular prevention trials including PROGRESS which has altered the management of stroke with all major guidelines now recommending routine blood pressure lowering in patients with a completed stroke; ONTARGET which has shown equivalent benefits of ACE inhibitors and Angiotension Receptor Blockers but adverse effects of their combination, in patients at high risk of cardiovascular disease; and HYVET confirming substantial benefits to be derived from anti-hypertensive treatment in very old people. He is currently leading studies to determine the effects of early intensive blood pressure lowering in acute intracerebral haemorrhage, and of CPAP for the prevention of recurrent stroke and heart attack.

CCRE role & involvement in CCRE projects

Professor Anderson will support the Professor Grunstein in his leadership of the CCRE executive committee, act as a Deputy Chair of meetings, and guarantee the CCRE governance and reporting functions. He will provide specific neurology, cardio/cerebro-vascular and ageing intellectual input into strategic direction of the CCRE and for key research projects. He will have a key leadership role on several scientific projects including the Sleep Apnea cardiovascular Endpoints (SAVE) trial which is evaluating the effects of CPAP treatment in preventing major cardiovascular events amongst 5,000 patients with co-existing cardiovascular disease and moderate-severe OSA who will be recruited from over 100 sites in Australia, New Zealand, China and India from 2008 to 2010.

Relevant publications

  1. PROGRESS Collaborative Group. (Writing committee: MacMahon S, Neal B, Tzourio C, Rodgers A, Woodward M, Cutler J, Anderson C and Chalmers J with assistance of Ohkubo T). Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041
  2. The ONTARGET Investigators. (Writing Committee: Yusuf S, Phil D, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
  3. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898.
  4. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Chen Y, Herietier S, Morgenstern LB, Chalmers J for the INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology 2008; 391-399.
  5. Anderson CS, Huang Y, Arima H, Heeley E, Skulina C, Parsons MW, Peng B, Li Q, Su S, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Morgenstern LB, Chalmers J, Wang JG; for the INTERACT Investigators. Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage. The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke. 2010 41:307-312.
  6. Arima H, Tzourio C, Anderson C, Woodward M, Bousser M-B, MacMahon S, Neal B, Chalmers J for the PROGRESS Collaborative Group. Effects of perindopril-based blood pressure lowering on probable cerebral amyloid angiopathy-related intracerebral hemorrhage: the PROGRESS trial. Stroke 2010. 41:394-396.